Abnormal fatty acid metabolism is a core component of spinal muscular atrophy

Marc‐Olivier Deguise, Giovanni Baranello, Chiara Mastella, Ariane Beauvais , Jean Michaud, Alessandro Leone, Ramona De Amicis, Alberto Battezzati, Christopher Dunham, Kathryn Selby, Jodi Warman Chardon, Hugh J. McMillan, Yu‐Ting Huang, Natalie L. Courtney, Alannah J. Mole, Sabrina Kubinski, Peter Claus, Lyndsay M. Murray, Melissa Bowerman, Thomas H. Gillingwater & 3 others Simona Bertoli, Simon H. Parson, Rashmi Kothary

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective
Spinal muscular atrophy (SMA) is an inherited neuromuscular disorder leading to paralysis and subsequent death in young children. Initially considered a motor neuron disease, extra‐neuronal involvement is increasingly recognized. The primary goal of this study was to investigate alterations in lipid metabolism in SMA patients and mouse models of the disease.

Methods
We analyzed clinical data collected from a large cohort of pediatric SMA type I–III patients as well as SMA type I liver necropsy data. In parallel, we performed histology, lipid analysis, and transcript profiling in mouse models of SMA.

Results
We identify an increased susceptibility to developing dyslipidemia in a cohort of 72 SMA patients and liver steatosis in pathological samples. Similarly, fatty acid metabolic abnormalities were present in all SMA mouse models studied. Specifically, Smn2B/‐ mice displayed elevated hepatic triglycerides and dyslipidemia, resembling non‐alcoholic fatty liver disease (NAFLD). Interestingly, this phenotype appeared prior to denervation.

Interpretation
This work highlights metabolic abnormalities as an important feature of SMA, suggesting implementation of nutritional and screening guidelines in patients, as such defects are likely to increase metabolic distress and cardiovascular risk. This study emphasizes the need for a systemic therapeutic approach to ensure maximal benefits for all SMA patients throughout their life.
Original languageEnglish
Pages (from-to)1519-1532
Number of pages14
JournalAnnals of Clinical and Translational Neurology
Volume6
Issue number8
Early online date26 Jul 2019
DOIs
Publication statusPublished - Aug 2019

Fingerprint

Spinal Muscular Atrophy
Fatty Acids
Dyslipidemias
Motor Neuron Disease
Muscular Atrophy
Liver
Denervation
Fatty Liver
Lipid Metabolism
Paralysis
Histology
Triglycerides
Guidelines
Pediatrics
Phenotype
Lipids

Keywords

  • MOTOR-NEURON PROTEIN
  • GLUCOSE-METABOLISM
  • INTRINSIC DEFECTS
  • CARDIAC DEFECTS
  • MOUSE MODEL
  • PREVALENCE
  • CHILDREN
  • LIVER
  • DYSLIPIDEMIA
  • ADOLESCENTS

Cite this

Deguise, MO., Baranello, G., Mastella, C., Beauvais , A., Michaud, J., Leone, A., ... Kothary, R. (2019). Abnormal fatty acid metabolism is a core component of spinal muscular atrophy. Annals of Clinical and Translational Neurology, 6(8), 1519-1532. https://doi.org/10.1002/acn3.50855

Abnormal fatty acid metabolism is a core component of spinal muscular atrophy. / Deguise, Marc‐Olivier; Baranello, Giovanni; Mastella, Chiara; Beauvais , Ariane; Michaud, Jean; Leone, Alessandro; De Amicis, Ramona; Battezzati, Alberto; Dunham, Christopher; Selby, Kathryn; Chardon, Jodi Warman; McMillan, Hugh J.; Huang, Yu‐Ting; Courtney, Natalie L.; Mole, Alannah J.; Kubinski, Sabrina; Claus, Peter; Murray, Lyndsay M.; Bowerman, Melissa; Gillingwater, Thomas H.; Bertoli, Simona; Parson, Simon H.; Kothary, Rashmi (Corresponding Author).

In: Annals of Clinical and Translational Neurology, Vol. 6, No. 8, 08.2019, p. 1519-1532.

Research output: Contribution to journalArticle

Deguise, MO, Baranello, G, Mastella, C, Beauvais , A, Michaud, J, Leone, A, De Amicis, R, Battezzati, A, Dunham, C, Selby, K, Chardon, JW, McMillan, HJ, Huang, YT, Courtney, NL, Mole, AJ, Kubinski, S, Claus, P, Murray, LM, Bowerman, M, Gillingwater, TH, Bertoli, S, Parson, SH & Kothary, R 2019, 'Abnormal fatty acid metabolism is a core component of spinal muscular atrophy', Annals of Clinical and Translational Neurology, vol. 6, no. 8, pp. 1519-1532. https://doi.org/10.1002/acn3.50855
Deguise, Marc‐Olivier ; Baranello, Giovanni ; Mastella, Chiara ; Beauvais , Ariane ; Michaud, Jean ; Leone, Alessandro ; De Amicis, Ramona ; Battezzati, Alberto ; Dunham, Christopher ; Selby, Kathryn ; Chardon, Jodi Warman ; McMillan, Hugh J. ; Huang, Yu‐Ting ; Courtney, Natalie L. ; Mole, Alannah J. ; Kubinski, Sabrina ; Claus, Peter ; Murray, Lyndsay M. ; Bowerman, Melissa ; Gillingwater, Thomas H. ; Bertoli, Simona ; Parson, Simon H. ; Kothary, Rashmi. / Abnormal fatty acid metabolism is a core component of spinal muscular atrophy. In: Annals of Clinical and Translational Neurology. 2019 ; Vol. 6, No. 8. pp. 1519-1532.
@article{9d1cc60e1ecc4071800572e30ecfbb29,
title = "Abnormal fatty acid metabolism is a core component of spinal muscular atrophy",
abstract = "ObjectiveSpinal muscular atrophy (SMA) is an inherited neuromuscular disorder leading to paralysis and subsequent death in young children. Initially considered a motor neuron disease, extra‐neuronal involvement is increasingly recognized. The primary goal of this study was to investigate alterations in lipid metabolism in SMA patients and mouse models of the disease.MethodsWe analyzed clinical data collected from a large cohort of pediatric SMA type I–III patients as well as SMA type I liver necropsy data. In parallel, we performed histology, lipid analysis, and transcript profiling in mouse models of SMA.ResultsWe identify an increased susceptibility to developing dyslipidemia in a cohort of 72 SMA patients and liver steatosis in pathological samples. Similarly, fatty acid metabolic abnormalities were present in all SMA mouse models studied. Specifically, Smn2B/‐ mice displayed elevated hepatic triglycerides and dyslipidemia, resembling non‐alcoholic fatty liver disease (NAFLD). Interestingly, this phenotype appeared prior to denervation.InterpretationThis work highlights metabolic abnormalities as an important feature of SMA, suggesting implementation of nutritional and screening guidelines in patients, as such defects are likely to increase metabolic distress and cardiovascular risk. This study emphasizes the need for a systemic therapeutic approach to ensure maximal benefits for all SMA patients throughout their life.",
keywords = "MOTOR-NEURON PROTEIN, GLUCOSE-METABOLISM, INTRINSIC DEFECTS, CARDIAC DEFECTS, MOUSE MODEL, PREVALENCE, CHILDREN, LIVER, DYSLIPIDEMIA, ADOLESCENTS",
author = "Marc‐Olivier Deguise and Giovanni Baranello and Chiara Mastella and Ariane Beauvais and Jean Michaud and Alessandro Leone and {De Amicis}, Ramona and Alberto Battezzati and Christopher Dunham and Kathryn Selby and Chardon, {Jodi Warman} and McMillan, {Hugh J.} and Yu‐Ting Huang and Courtney, {Natalie L.} and Mole, {Alannah J.} and Sabrina Kubinski and Peter Claus and Murray, {Lyndsay M.} and Melissa Bowerman and Gillingwater, {Thomas H.} and Simona Bertoli and Parson, {Simon H.} and Rashmi Kothary",
note = "{\circledC} 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.",
year = "2019",
month = "8",
doi = "10.1002/acn3.50855",
language = "English",
volume = "6",
pages = "1519--1532",
journal = "Annals of Clinical and Translational Neurology",
issn = "2328-9503",
publisher = "Wiley",
number = "8",

}

TY - JOUR

T1 - Abnormal fatty acid metabolism is a core component of spinal muscular atrophy

AU - Deguise, Marc‐Olivier

AU - Baranello, Giovanni

AU - Mastella, Chiara

AU - Beauvais , Ariane

AU - Michaud, Jean

AU - Leone, Alessandro

AU - De Amicis, Ramona

AU - Battezzati, Alberto

AU - Dunham, Christopher

AU - Selby, Kathryn

AU - Chardon, Jodi Warman

AU - McMillan, Hugh J.

AU - Huang, Yu‐Ting

AU - Courtney, Natalie L.

AU - Mole, Alannah J.

AU - Kubinski, Sabrina

AU - Claus, Peter

AU - Murray, Lyndsay M.

AU - Bowerman, Melissa

AU - Gillingwater, Thomas H.

AU - Bertoli, Simona

AU - Parson, Simon H.

AU - Kothary, Rashmi

N1 - © 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.

PY - 2019/8

Y1 - 2019/8

N2 - ObjectiveSpinal muscular atrophy (SMA) is an inherited neuromuscular disorder leading to paralysis and subsequent death in young children. Initially considered a motor neuron disease, extra‐neuronal involvement is increasingly recognized. The primary goal of this study was to investigate alterations in lipid metabolism in SMA patients and mouse models of the disease.MethodsWe analyzed clinical data collected from a large cohort of pediatric SMA type I–III patients as well as SMA type I liver necropsy data. In parallel, we performed histology, lipid analysis, and transcript profiling in mouse models of SMA.ResultsWe identify an increased susceptibility to developing dyslipidemia in a cohort of 72 SMA patients and liver steatosis in pathological samples. Similarly, fatty acid metabolic abnormalities were present in all SMA mouse models studied. Specifically, Smn2B/‐ mice displayed elevated hepatic triglycerides and dyslipidemia, resembling non‐alcoholic fatty liver disease (NAFLD). Interestingly, this phenotype appeared prior to denervation.InterpretationThis work highlights metabolic abnormalities as an important feature of SMA, suggesting implementation of nutritional and screening guidelines in patients, as such defects are likely to increase metabolic distress and cardiovascular risk. This study emphasizes the need for a systemic therapeutic approach to ensure maximal benefits for all SMA patients throughout their life.

AB - ObjectiveSpinal muscular atrophy (SMA) is an inherited neuromuscular disorder leading to paralysis and subsequent death in young children. Initially considered a motor neuron disease, extra‐neuronal involvement is increasingly recognized. The primary goal of this study was to investigate alterations in lipid metabolism in SMA patients and mouse models of the disease.MethodsWe analyzed clinical data collected from a large cohort of pediatric SMA type I–III patients as well as SMA type I liver necropsy data. In parallel, we performed histology, lipid analysis, and transcript profiling in mouse models of SMA.ResultsWe identify an increased susceptibility to developing dyslipidemia in a cohort of 72 SMA patients and liver steatosis in pathological samples. Similarly, fatty acid metabolic abnormalities were present in all SMA mouse models studied. Specifically, Smn2B/‐ mice displayed elevated hepatic triglycerides and dyslipidemia, resembling non‐alcoholic fatty liver disease (NAFLD). Interestingly, this phenotype appeared prior to denervation.InterpretationThis work highlights metabolic abnormalities as an important feature of SMA, suggesting implementation of nutritional and screening guidelines in patients, as such defects are likely to increase metabolic distress and cardiovascular risk. This study emphasizes the need for a systemic therapeutic approach to ensure maximal benefits for all SMA patients throughout their life.

KW - MOTOR-NEURON PROTEIN

KW - GLUCOSE-METABOLISM

KW - INTRINSIC DEFECTS

KW - CARDIAC DEFECTS

KW - MOUSE MODEL

KW - PREVALENCE

KW - CHILDREN

KW - LIVER

KW - DYSLIPIDEMIA

KW - ADOLESCENTS

UR - http://www.mendeley.com/research/abnormal-fatty-acid-metabolism-core-component-spinal-muscular-atrophy

U2 - 10.1002/acn3.50855

DO - 10.1002/acn3.50855

M3 - Article

VL - 6

SP - 1519

EP - 1532

JO - Annals of Clinical and Translational Neurology

JF - Annals of Clinical and Translational Neurology

SN - 2328-9503

IS - 8

ER -